Eric Berthelet¹, Tom Pickles², Pauline T. Truong¹, Mitchell Liu³, Howard H. Pai¹, Winkle B. Kwan³, Jan T.W. Lim¹

Canadian Journal of Urology, Vol.14, No.4, pp. 3621-3627, 2007

Abstract Purpose: To evaluate the optimal duration of androgen deprivation therapy (ADT) in patients with prostate cancer treated with external beam radiotherapy (EBRT), who present with PSA levels >20 ng/mL.
Materials and methods: A total of 307 patients presenting with a PSA >20 ng/ml were treated with EBRT and ADT. The cohort was divided into four groups according to the duration of ADT: Group 1 received <6 months (n=71), group 2 received 6-12 months (n=80), group 3 received 12-24 months (n=72), and group 4 received >24 months (n=84) of ADT. The endpoints analyzed were biochemical control (bNED), overall… More >

Lambda P. Msezane, Ofer N. Gofrit, Shang Lin, Arieh L. Shalhav, Gregory P. Zagaja, Kevin C. Zorn

Canadian Journal of Urology, Vol.14, No.5, pp. 3697-3701, 2007

Abstract Introduction: Pre-operative prediction of pathological stage represents the cornerstone of prostate cancer management. Patient counseling is routinely based on pre-operative PSA, Gleason score and clinical stage. In this study, we evaluated whether prostate weight (PW) is an independent predictor of extracapsular extension (ECE) and positive surgical margin (PSM).
Methods: Between February 2003 and November 2006, 709 men underwent robotic-assisted laparoscopic radical prostatectomy (RLRP). Pre-operative parameters (patient age, pre-operative PSA, biopsy Gleason score, clinical stage) as well as pathological data (prostate weight, pathological stage) were prospectively gathered after internal-review board (IRB) approval. Evaluation of the influence of… More >

S. Marwaha, P. M. Venner, S. A. North

Canadian Journal of Urology, Vol.14, No.5, pp. 3692-3696, 2007

Abstract Objective: The primary objective was to evaluate the effect of etoposide dose in a 3-day cisplatin/etoposide/bleomycin (PEB) regimen on progression free survival (PFS) and overall survival (OS). Secondary objectives were to determine the impact of a paclitaxel-based salvage regimen on OS and to compare the risk distribution of germ cell patients seen at a tertiary care center to that quoted in the International Germ Cell Consensus Classification (IGCCC).
Methods: A retrospective chart review of all 302 metastatic germ cell patients requiring cisplatin-based chemotherapy between January 1980 and December 2004 was conducted. Data collected on initial treatment… More >

Nicolas Barry Delongchamps, Michaël Peyromaure

Canadian Journal of Urology, Vol.14, No.5, pp. 3669-3677, 2007

Abstract Background: Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis, but has also been implicated in pathological angiogenesis associated with renal cell carcinoma (RCC) and prostate cancer (PCa).
Material and methods: This review of literature underlines the recent advances in the understanding of how VEGF acts through these two malignancies, its potential value as a diagnostic and prognostic marker, as well as the development of new therapeutic strategies targeting the VEGF pathway.
Results: In RCC, VHL gene inactivation mediates overexpression of VEGF. Multiple approaches to block VEGF signaling in kidney cancer have been tested.… More >

Gabriel P. Haas

Canadian Journal of Urology, Vol.14, No.5, pp. 3668-3668, 2007

Abstract This article has no abstract. More >

Yoh Matsuoka^1,3, Gaku Arai¹, Hisashi Ishimaru¹, Kentaro Takagi¹, Yuji Ito²

Canadian Journal of Urology, Vol.14, No.6, pp. 3764-3766, 2007

Abstract We report a rare case of primary signet-ring cell carcinoma of the prostate in an advanced stage. A 62-year-old man with serum level of prostate-specific antigen at 364.70 ng/ml was diagnosed as having cT4N1M1c prostatic signet-ring cell carcinoma of Gleason score 5 + 4 = 9. Immunohistochemical examination demonstrated cytoplasmic immunoreactivity to prostate-specific antigen in signet-ring cancer cells. The intracytoplasmic vacuoles in the signet-ring cells showed mucin production with a positive staining with periodic acid-Schiff. Although the patient received hormonal therapy, the disease progressed and lead to death 15 months after the diagnosis. The clinical More >

A. Hameed, N. Sezian, A. Thwaini

Canadian Journal of Urology, Vol.14, No.6, pp. 3745-3749, 2007

Abstract Introduction: We are reporting a case of bladder contracture post intravesical bacillus Calmette-Guerin (BCG) therapy; to our knowledge only two cases were reported. We present the clinical history/presentation, investigation and the outcome of the treatment. Approximately 75%-85% of patients with bladder cancer present with disease confined to the mucosa (stage Ta-CIS) or submucosa (stage T1). The management of non-muscle invasive bladder cancer has become more complex with regard to initial investigation, treatment and follow-up. In high-grade tumors, BCG therapy has proven to be superior to intravesical chemotherapy. BCG therapy prevents, or at least delays, tumor progression.… More >

Felix K-H. Chun¹, Nazareno Suardi¹, Paul Perrotte², Thierry Lebeau², Jean-Pierre Guay², Serge Benayoun², Alvaro Ramirez², François Bénard², Michael McCormack², Luc Valiquette², Pierre Karakiewicz^1,2

Canadian Journal of Urology, Vol.14, No.6, pp. 3727-3733, 2007

Abstract Introduction: Controversy persists about whether men should be screened for prostate cancer. On the other hand, the benefit of colorectal cancer screening has been proven for men starting at age 50. We aimed to examine the rate of exposure to previous screening tests for prostate cancer and colorectal cancer in a cohort of men living in Quebec.
Materials and methods: As part of an event promoting early prostate cancer detection, 347 men aged 50 to 69 without an established diagnosis of prostate cancer agreed to reply to questions in a previously validated questionnaire. The self-administered questionnaire, which… More >

M. Sánchez Negrette, M.A. Montenegro, M.S. Catuogno, W.J. Lértora, M.C. Guanziroli

BIOCELL, Vol.31, No.3, pp. 391-396, 2007, DOI:10.32604/biocell.2007.31.391

Abstract Epidemiological studies in human beings and experimental studies in laboratory animals suggest that milk and dairy products can inhibit effects on the development of some kinds of tumors. Cow milk contains sphingomyelin, butyric acid, conjugated linoleic acid, calcium, vitamin A, carotene and vitamin D. All of these components are known to inhibit the process of carcinogenesis. Our objective was to determine the effect of cow milk and water buffalo milk on the development of colon neoplasias in an experimental model of carcinogenesis in rats induced with 1,2-dimethylhydrazine (DMH). Three-month-old Wistar male rats with an average… More >

European Cytokine Network, Vol.17, Suppl.1, pp. 88-97, 2006

Abstract This article has no abstract. More >